CHANGE THE WORLD.

Autor: Heimer, Matt (AUTHOR), Ajemian, Nina (AUTHOR), Brady, Diane (AUTHOR), Brice, Jenn (AUTHOR), Burleigh, Emma (AUTHOR), Daniel, Will (AUTHOR), del Castillo, Michael (AUTHOR), Freedman, Ani (AUTHOR), Greenfield, Beth (AUTHOR), Lim, Lionel (AUTHOR), MacLellan, Lila (AUTHOR), McKenna, Greg (AUTHOR), Racine, Imani (AUTHOR), Rogelberg, Sasha (AUTHOR), Stoller, Kristin (AUTHOR), Wahba, Phil (AUTHOR)

Publikováno v: Fortune. Oct/Nov2024, Vol. 190 Issue 2, p85-98. 12p. 14 Color Photographs, 1 Diagram.

Mifepristone and misoprostol in California pharmacies after modifications to the Risk Evaluation and Mitigation Strategy Program.

Autor: Beshar I; Department of Obstetrics & Gynecology, Stanford University, Palo Alto, CA, USA. Electronic address: isabel.beshar@gmail.com., Miller HE; Division of Maternal Fetal Medicine, Stanford University, CA, USA., Kruger S; Department of Obstetrics & Gynecology, Stanford University, Palo Alto, CA, USA., Henkel A; Division of Family Planning, Department of Obstetrics & Gynecology, Stanford University, Palo Alto, CA, USA.

Publikováno v: Contraception [Contraception] 2024 Sep; Vol. 137, pp. 110506. Date of Electronic Publication: 2024 May 26.

Reimagining democracy.

Autor: Spinney, Laura (AUTHOR)

Publikováno v: New Scientist. 10/5/2024, Vol. 264 Issue 3511, p32-35. 4p. 6 Color Photographs.

Production and decarbonisation of conventional gasoline vehicle automakers under subsidy and regulation policies.

Autor: Pi, Zhenyang^1,2,3,4 (AUTHOR) zypi@bit.edu.cn

Publikováno v: International Journal of Production Research. Sep2024, Vol. 62 Issue 18, p6823-6841. 19p.

How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians.

Autor: Sarpatwari A; Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Lu Z; Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Russo M; Harvard Medical School, Boston, Massachusetts, USA.; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Zakoul H; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Lee SB; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Toyserkani GA; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Zhou EH; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., LaCivita C; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Shaw KHH; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Zendel L; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Dal Pan GJ; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Kesselheim AS; Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Jun; Vol. 115 (6), pp. 1293-1303. Date of Electronic Publication: 2024 Feb 20.